Clinical Trial

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-02-10; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-02-25
Trial Details
NCT Number NCT06826612
Lead Sponsor Hoffmann-La Roche
Conditions Huntington Disease
Enrollment 53 participants
Start Date 2025-02-21
Primary Completion 2035-01-12 (estimated)
Study Completion 2035-01-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-05